Clinical trials: Metastatic NSCLC - Non-Small Cell Lung Cancer
- Condition Metastatic NSCLC - Non-Small Cell Lung Cancer
- Funder type Industry (pharma, biotech, devices)
Stage IV Non-small Cell Lung Cancer
MTD Study PXD-101 in Combination With Paclitaxel + Carboplatin in Chemotherapy-Naive Patients With Stage IV NSCLC
To define Phase 1/2 Maximum Tolerated Dose Study of Belinostat (PXD-101) in Combination with Paclitaxel plus Carboplatin in Chemotherapy-Naive Patients with Stage IV Non-Small-Cell Lung Cancer (NSCLC).
- Trial name
- NCT01310244
- Testing
- Belinostat, Carboplatin, Paclitaxel
- Where
- 4 sites in United States
- Volunteers
- 23 people
- Sponsor
- Acrotech Biopharma Inc.
Non-small Cell Lung Cancer
A Phase 1b/2 Study of Safety and Efficacy of Rociletinib in Combination With MPDL3280A in Patients With Advanced or Metastatic EGFR-mutant NSCLC
This clinical research study is being carried out in two parts, Phase 1 and Phase 2. The primary purpose of the Phase 1 portion of the study is to observe the safety of the combination of rociletinib and MPDL3280A in EGFR-mutant…
- Trial name
- NCT02630186
- Testing
- Rociletinib, MPDL3280A
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Clovis Oncology, Inc.
Non Small Cell Lung Cancer
An Observational Study to Evaluate AZD9291 Treatment in Patients With T790M Positive Non-small Cell Lung Cancer
AZD9291 Early Access Program (EAP) was available in Taiwan during October 2015 to September 2016, a time period before the approval of AZD9291, to supply the unlicensed AZD9291 for the NSCLC patients who received at least one…
- Trial name
- NCT03457220
- Where
- 7 sites in Taiwan
- Volunteers
- 423 people
- Sponsor
- AstraZeneca
Non-Small Cell Lung Cancer, Neoplasm Metastasis
ABX-EGF in Combination With Paclitaxel and Carboplatin for the Treatment of Advanced Non-Small-Cell Lung Cancer (NSCLC)
Rationale: Overexpression of epidermal growth factor receptor (EGFR) has been observed in kidney, prostate, colon, lung, breast, and other cancers, and is often associated with a poor prognosis.
- Conditions
- Non-Small Cell Lung Cancer, Neoplasm Metastasis, Lung Cancer
- Trial name
- NCT00034346
- Testing
- ABX-EGF, paclitaxel, carboplatin
- Volunteers
- 194 people
- Sponsor
- Amgen
KRAS p, G12c Mutated /Advanced Metastatic NSCLC
Study to Compare AMG 510 "Proposed INN Sotorasib" With Docetaxel in Non Small Cell Lung Cancer (NSCLC) (CodeBreak 200).
A Phase 3 Study to Compare AMG 510 with Docetaxel in Non Small Cell Lung Cancer (NSCLC) subjects with KRAS p. G12c mutation
- Trial name
- NCT04303780
- Testing
- AMG 510, Docetaxel
- Where
- 274 sites in United States, Australia and 21 more
- Volunteers
- 345 people
- Sponsor
- Amgen
Advanced Solid Tumors, Metastatic Solid Tumors
A Dose Escalation Study Of PF-06939999 In Participants With Advanced Or Metastatic Solid Tumors
This is a Phase 1, open label, multi center, dose escalation and expansion, safety, tolerability, PK, and pharmacodynamics study of PF 06939999 in previously treated patients with advanced or metastatic cancer.
- Trial name
- NCT03854227
- Testing
- PF-06939999 dose escalation, PF-06939999 monotherapy, PF-06939999 in combination with docetaxel
- Where
- 22 sites in United States
- Volunteers
- 54 people
- Sponsor
- Pfizer
Solid Tumor, Adult, Epithelial Ovarian Cancer
Study of CBX-12 in Subjects With Advanced or Metastatic Refractory Solid Tumors
This is a first-in-human, Phase 1/2 open-label, multicenter, dose-escalation, safety, pharmacokinetics (PK), and biomarker study of CBX-12 in subjects with advanced or metastatic refractory solid tumors.
- Conditions
- Solid Tumor, Adult, Epithelial Ovarian Cancer, Small Cell Lung Carcinoma, Breast Cancer
- Trial name
- NCT04902872
- Testing
- CBX-12
- Where
- 4 sites in United States
- Volunteers
- 69 people
- Sponsor
- Cybrexa Therapeutics
Non-small Cell Lung Cancer Stage IV
A Study to Compare the Efficacy, Safety, Pharmacokinetics, and Immunogenicity Between SB27 and Keytruda in Subjects With Metastatic Non-squamous Non-small Cell Lung Cancer
The goal of this clinical trial is to confirm that SB27 works in the same way as Keytruda in metastatic non-squamous non-small cell lung cancer (NSCLC) patients.
- Trial name
- NCT06348199
- Testing
- SB27, Keytruda
- Where
- 93 sites in Bosnia and Herzegovina, Brazil and 12 more
- Volunteers
- 555 people
- Sponsor
- Samsung Bioepis Co., Ltd.
Carcinoma, Non-Small-Cell Lung
ALIMTA Plus Carboplatin as Front-Line Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer: A Phase 2 Clinical Trial.
The purpose of this study is to evaluate the effects (good and bad) of LY231514 (ALIMTA) and Carboplatin on you and your non-small cell lung cancer.
- Trial name
- NCT00051493
- Testing
- ALIMTA, Carboplatin
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Eli Lilly and Company
Ovarian Cancer, Small Cell Lung Cancer
A Study of LG00313112 in Participants With Advanced Solid Malignancies Harboring a TP53 Y220C Mutation
This is a first-in-human, Phase 1/2, open-label study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of LG00313112 in participants with advanced solid malignancies harboring a TP53 Y220C…
- Conditions
- Ovarian Cancer, Small Cell Lung Cancer, Non Small Cell Lung Cancer, Colorectal Cancer
- Trial name
- NCT07752875
- Testing
- LG00313112
- Volunteers
- 250 people
- Sponsor
- LG Chem
Metastatic Non-Small Cell Lung Cancer
Pre-Approval Access With Amivantamab (JNJ-61186372) in Participants With Metastatic Non-Small Cell Lung Cancer
The purpose of this expanded access program (EAP) is to provide amivantamab for the treatment of participants with metastatic non-small cell lung cancer who have epidermal growth factor receptor exon 20 insertion mutations, and…
- Trial name
- NCT04599712
- Testing
- Amivantamab
- Sponsor
- Janssen Research & Development, LLC
Non-small Cell Lung Cancer
A Study of BL-M07D1 in Patients With HER2-Overexpressing or HER2-Mutant Locally Advanced or Metastatic Non-Small Cell Lung Cancer
This phase Ib/II study is designed to evaluate the safety, tolerability, pharmacokinetics, and efficacy of injectable BL-M07D1 in patients with HER2-mutated, locally advanced or metastatic non-small cell lung cancer.
- Trial name
- NCT06114511
- Testing
- BL-M07D1
- Where
- China
- Volunteers
- 78 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
NSCLC
SKB264 in Combination With SKB118 for Non-Small Cell Lung Cancer
This is an open-label, multi-center, Phase II clinical study to evaluate the safety, tolerability, and efficacy of SKB264 in combination with SKB118 in participants with NSCLC.
- Trial name
- NCT07697586
- Testing
- SKB264+SKB118
- Where
- 2 sites in China
- Volunteers
- 206 people
- Sponsor
- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Non Small Cell Lung Cancer, Solid Tumor
A Study of BL-M24D1 in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer and Other Solid Tumors
This study is an open, multicenter, non-randomized phase I clinical trial to evaluate the safety, tolerability, pharmacokinetic characteristics, and preliminary efficacy of BL-M24D1 in patients with locally advanced or metastatic…
- Trial name
- NCT07232420
- Testing
- BL-M24D1
- Where
- China
- Volunteers
- 33 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Locally Advanced or Metastatic NSCLC
A Study of HS-10504 in Patients With Advanced or Metastatic Non-Small-Cell Lung Cancer(NSCLC)
HS-10504 is a fourth-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor targeting EGFR C797S mutation.
- Trial name
- NCT06461156
- Testing
- HS-10504
- Where
- China
- Volunteers
- 230 people
- Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
Solid Tumor (Phase I), Ovarian Cancer
A Study to Evaluate YF550 in Participants With Locally Advanced or Metastatic Solid Tumors.
This study is a open-label, multicenter clinical trials. The target population is participants with locally advanced or metastatic solid tumors. A total of 204 participants are planned to be included.
- Conditions
- Solid Tumor (Phase I), Ovarian Cancer, NSCLC (Advanced Non-small Cell Lung Cancer), TNBC - Triple-Negative Breast Cancer
- Trial name
- NCT07894874
- Testing
- YF550
- Volunteers
- 204 people
- Sponsor
- InventisBio Yiqi Beijing Limited
Triple Negative Breast Cancer, Non-small Cell Lung Cancer
A Biomarker Screening Protocol for Participants With Solid Tumors
Biomarker Screening Protocol for Preliminary Eligibility Determination for Adoptive T-cell Therapy Trials:This is a decentralized, multi-site, US-based biomarker screening study to identify participants who have specific disease…
- Conditions
- Triple Negative Breast Cancer, Non-small Cell Lung Cancer, Non Small Cell Lung Cancer, Non Small Cell Lung Cancer Metastatic
- Trial name
- START (NCT05891197)
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Lyell Immunopharma, Inc.
EGFR Mutation-positive Inoperable or Reccrent NSCLC
Special Investigation for VIZIMPRO Tablets (Secondary Data Collection Study; Safety and Efficacy of VIZIMPRO Under Japanese Medical Practice)
Secondary data collection study: safety and efficacy of VIZIMPRO under Japanese medical practice
- Trial name
- NCT04155541
- Testing
- dacomitinib hydrate
- Where
- Japan
- Volunteers
- 40 people
- Sponsor
- Pfizer
Carcinoma, Non-Small Cell Lung
CPG 7909 Injection in Non-Small Cell Lung Cancer
Eligible patients will be randomized in a ratio of 2:1 to receive either chemotherapy (a taxane and a platinum compound) plus CPG 7909 Injection or chemotherapy alone.
- Trial name
- NCT00070629
- Testing
- CPG 7909, Chemotherapy
- Where
- 24 sites in United States, Canada and 1 more
- Volunteers
- 116 people
- Sponsor
- Pfizer
Non-Small Cell Lung Cancer, Advanced Solid Tumors
A Phase Ib Study of HS-10370 in Addition to Other Anti-cancer Therapies in Participants with KRAS G12C Mutation Advanced Solid Tumors
This is a Phase Ib study that will evaluate the Safety, Tolerability , Pharmacokinetics and Activity of HS-10370 in Combination With Other Anti-cancer Therapies in patients with KRAS G12C mutation advanced or metastatic solid…
- Trial name
- NCT06594874
- Testing
- HS-10370, Adebrelimab, Cisplatin
- Where
- China
- Volunteers
- 350 people
- Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.